Notice: This document has been translated from a part of the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

Consolidated Financial Results for the Six Months Ended September 30, 2026 [Under Japanese GAAP]

November 9, 2026
Tokyo Stock Exchange

Company name: KYORIN Pharmaceutical Co., Ltd.
Code number: 4569
Web site: https://www.kyorin-pharm.co.jp/
Representative: Yutaka Ogihara, Representative Director, President and Chief Executive Officer
Contact: Sakurou Banba, Director, Finance & Accounting
TEL (03) 6374-9704
Scheduled date to file semi-annual securities report: November 16, 2026
Scheduled date to commence dividend payments: December 2, 2026
Preparation of supplementary material on financial results: Yes
Holding of financial results briefing: Yes (for analysts and institutional investors)

(Amounts rounded down to the nearest million yen)

1. Consolidated results for the six months ended September 30, 2026 (from April 1, 2026 to September 30, 2026)

(1) Consolidated operating results

(Percentage changes relative to previous corresponding period)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent	
Six months ended	Million yen	%	Million yen	%	Million yen	%	Million yen	%
September 30, 2026	57,489	−2.1	306	−77.6	689	−56.4	−1,566	—
September 30, 2025	58,731	6.5	1,363	−12.0	1,582	−22.8	1,494	19.0

(Note) Comprehensive income: For the six months ended September 30, 2026: −2,535 million yen (−%),
For the six months ended September 30, 2025: 2,308 million yen (100.3%)

	Basic earnings per share	Diluted earnings per share
Six months ended	Yen	Yen
September 30, 2026	−27.26	—
September 30, 2025	26.01	—

(2) Consolidated financial position

	Total assets	Net assets	Equity-to-asset ratio
As of	Million yen	Million yen	%
September 30, 2026	186,819	138,057	73.9
March 31, 2026	195,455	142,425	72,9

(Note) Equity: As of September 30, 2026: 138,057 million yen,
As of March 31, 2026: 142,425 million yen

2. Cash dividends

	Annual dividends per share				
(Record date)	First quarter-end	Second quarter-end	Third quarter-end	Fiscal year-end	Total
	Yen	Yen	Yen	Yen	Yen
Fiscal year ended March 31, 2026	—	20.00	—	37.00	57.00
Fiscal year ending March 31, 2027	—	10.00			
Fiscal year ending March 31, 2027 (Forecast)			—	15.00	25.00

(Note) Revisions to the dividend forecast in the current quarter: None

3. Forecast of consolidated for the year ending March 31, 2027 (from April 1, 2026 to March 31, 2027)

(Percentage changes relative to previous corresponding period)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent		Earnings per share
	Million yen	%	Million yen	%	Million yen	%	Million yen	%	Yen
Full year	121,800	−3,5	−4,900	—	−4,600	—	−5,100	—	−88.74

(Note) Revisions to the financial forecast in the current quarter: Yes

4. Other

(1) Changes in significant subsidiaries during the period (Change in specified subsidiaries resulting in the scope of consolidation): None
Newly included: None, Excluded: None

(2) Adoption of accounting treatment specific to the preparation of quarterly financial statements : Yes

(3) Changes in accounting policies, changes in accounting estimates and restatements

(i)	Changes in accounting policies due to revisions to accounting standards and other regulations	:None
(ii)	Changes in accounting policies due to other than (i)	:None
(iii)	Changes in accounting estimates	:None
(iv)	Restatements	:None

(3) Number of issued shares (common stock)

(i) Number of issued shares at the end of the period (including treasury shares):

As of September 30, 2026	59,945,641 shares,
As of March 31, 2026	59,945,641 shares

(ii) Number of treasury shares at the end of the period:

As of September 30, 2026	2,353,573 shares,
As of March 31, 2026	2,499,346 shares

(iii) Average number of shares outstanding during the period:

Six months ended September 30, 2026	57,471,763 shares,
Six months ended September 30, 2025	57,449,310 shares

* Semi-annual financial results reports are exempt from review conducted by certified public accountants or an audit firm.
* Explanations about the appropriate use of the business forecasts and other noteworthy points.
These forecast performance figures are based on information currently available to the Company and may include uncertain factors or risk that affect our future performance. Accordingly, actual business results may materially differ from the forecasted figures due to various factors in the future.

(Methods for obtaining supplementary materials and content of financial results disclosure)
The Company plans to hold a financial results briefing for analysts and institutional investors on November 10, 2026. Supplementary materials will be made available on the Company's website in conjunction with the Summary of Consolidated Financial Results.